Cooperativity of α-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human

References

• CUPP-VICKERY, J., ANDERSON, R. and HATZIRIS, Z., 2000, Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity. Proceedings of National Academy of Sciences, USA, 97, 3050–3055.
   PubMed Web of Science ®Google Scholar
• DOMANSKI, T. L., HE, Y. A., HARLOW, G. R. and HALPERT, J. R., 2000, Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. Journal of Pharmacology and Experimental Therapeutics, 293, 585–591.
   PubMed Web of Science ®Google Scholar
• DOMANSKI, T. L., Liu, J., HARLOW, G. R. and HALPERT, J. R., 1998, Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: Role in steroid hydroxylase activity and a-naphthofiavone stimulation. Archives of Biochemistry and Biophysics, 350, 223–232.
   PubMed Web of Science ®Google Scholar
• EDGAR, B., BAILEY, D. G., BERGS TRAND, R., JOHNSSON, G. and LuRjE, L., 1990, Formulation dependent interaction between felodipine and grapefruit juice. Clinical Pharmacology and Therapeutics, 47, 181.
   Google Scholar
• EMOTO, C., YAMAZAKI, H., YAMASAKI, S., SHIMADA, N., NAKADMA, M. and YOKOI, T., 2000a, Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activities in vitro. Xenobiotica, 30, 971–982.
   PubMed Web of Science ®Google Scholar
• EMOTO, C., YAMAZAKI, H., YAMASAKI, S., SHIMADA, N., NAKADMA, M. and YOKOI, T., 2000b, Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. Xenobiotica, 30, 943–953.
   PubMed Web of Science ®Google Scholar
• GIBBS, M. A., THUMMEL, K. E., SHEN, D. D. and KUNZE, K. L., 1999, Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of K, values and impact of CYP3A5 expression. Drug Metabolism and Disposition, 27, 180–187.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1991, Reactions and significance of cytochrome P-450 enzymes. Journal of Biological Chemistry, 266, 10019–10022.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1995, Human cytochrome P450 enzymes. In P. R. Oritiz de Montellano (ed), Cytochrome P450 (New York: Plenum), pp. 473–535.
   Google Scholar
• HARLOW, G. R. and HALPERT, J. R., 1998, Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proceedings of National Academy of Sciences, USA, 95, 6636–6641.
   PubMed Web of Science ®Google Scholar
• HOSEA, N. A., MILLER, G. P. and GUENGERICH, F. P., 2000, Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry, 39, 5929–5939.
   PubMed Web of Science ®Google Scholar
• HOUSTON, J. B. and KENWORTHY, K. E., 2000, In vitro in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metabolism and Disposition, 28, 246–254.
   PubMed Web of Science ®Google Scholar
• IATSIMIRSKAIA, E., TULEBAEV, S., STOROZHUK, E., UTKIN, I., SMITH, D., GERBER, N. and KOUDRIAKOVA, T., 1997, Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clinical Pharmacology and Therapeutics, 61, 554–562.
   PubMed Web of Science ®Google Scholar
• KENWORTHY, K. E., BLOOMER, J. C., CLARICE, S. E. and HOUSTON, J. B., 1999, CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. British Journal of Clinical Pharmacology, 48, 716–727.
   PubMed Web of Science ®Google Scholar
• KORZEKWA, K. R., KRISHNAMACHARY, N., Suou, M., OGAI, A., PARISE, R. A., RETTIE, A. E., GONZALEZ, F. J. and TRACY, T. S., 1998, Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry, 37, 4137–4147.
   PubMed Web of Science ®Google Scholar
• KRISHNA, D. R. and KLOTZ, U., 1994, Extrahepatic metabolism of drugs in humans. Clinical Pharmacokinetics, 26, 144–160.
   PubMed Web of Science ®Google Scholar
• LALONDE, R. L., LESSARD, D. and GAUDREAULT, J., 1996, Population pharmacokinetics of terfenadine. Pharmaceutical Research, 13, 832–838.
   Google Scholar
• LOWN, K. S., Guosu, M. and WATKINS, P. B., 1998, Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. Drug Metabolism and Disposition, 26, 185–187.
   PubMed Web of Science ®Google Scholar
• LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• MA, B., PRUEKSARITANONT, T. and LIN, J. H., 2000, Drug interactions with calcium channel blockers: possible involvement of metaboliteintermediate complexation with CYP3A. Drug Metabolism and Disposition, 28, 125–130.
   PubMed Web of Science ®Google Scholar
• MÁENPAW, J., HALL, S. D., RING, B. J., STROM, S. C. and WEIGH-roN, S. A., 1998, Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by a-naphthofiavone, terfenadine and testosterone. Pharmacogenetics, 8, 137–155.
   Google Scholar
• NAKAMURA, T., OKADA, K., NAGATA, K. and YAMAZOE, Y., 2000, Intestinal cytochrome P450 and response to rifampicin in rabbits. Japanese Journal of Pharmacology, 82, 232–239.
   PubMedGoogle Scholar
• PAINE, M. F., KHALIctu, M., FISHER, J. M., SHEN, D. D., KUNZE, K. L., MARSH, C. L., PARKINS, J. D. and THUMMEL, K. E., 1997, Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. Journal of Pharmacology and Experimental Therapeutics, 283, 1552–1562.
   PubMed Web of Science ®Google Scholar
• PAINE, M. F., SHEN, D. D., KUNZE, K. L., PERKINS, J. D., MARSH, C. L., McVicAR, J. P., BARR, D. M., Gamm.s, B. S. and THUMMEL, K. E., 1996, First-pass metabolism of midazolam by the human intestine. Clinical Pharmacology and Therapeutics, 60, 14–24.
   Google Scholar
• SHET, M. S., FISHER, C. W., HOLMANS, P. L. and ESTABROOK, R. W., 1993, Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proceedings of National Academy of Sciences, USA, 90, 11748–11752.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• Suou, M., GROGAN, J., MANCEWICW, J. A., KRAUSZ, K. W., GONZALEZ, F. J., GELBOIN, H. V. and KORZEKWA, K. R., 1994, Activation of CYP3A4: Evidence for the simultaneous binding of substrates in a cytochrome P450 active site. Biochemistry, 33, 6450–6455.
   Google Scholar
• Smuni, M. T., EADIE, M. J. and BROPHY, T. O. R., 1981, The pharmacokinetics of midazolam in man. European Journal of Clinical Pharmacology, 19, 271–278.
   Google Scholar
• SZKLARZ, G. D. and HALPERT, J. R., 1997, Molecular modeling of cytochrome P450 3A4. Journal of Computer-Aided Molecular Design, 11, 265–272.
   PubMed Web of Science ®Google Scholar
• UENG, Y.-F., KUWABARA, T., CHUN, Y.-J. and GUENGERICH, F. P., 1997, Cooperativity in oxidations catalysed by cytochrome P450 3A4. Biochemistry, 36, 370–381.
   PubMed Web of Science ®Google Scholar
• WANG, H. F., DICK, R., YIN, H. Q., LICAD-COLES, E., KROETZ, D. L., SZKLARZ, G., HARLOW, G., HALPERT, J. R. and CORREIA, M. A., 1998, Structurefunction relationships of human liver cytochromes P450 3A: afiatoxin B1 metabolism as a probe. Biochemistry, 37, 12536–12545.
   Google Scholar
• WANG, R. W., NEwroN, D. J., Lm, N., ATKINS, W. M. and Lu, A. Y. H., 2000, Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metabolism and Disposition, 28, 360–366.
   PubMed Web of Science ®Google Scholar
• WATKINS, P. B., WEIorrroN, S. A., SCHUETZ, E. G., MOLOWA, D. T. and GUZELIAN, P. S., 1987, Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. Journal of Clinical Investigation, 80, 1029–1036.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H. and SHEMADA, T., 1997, Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Archives of Biochemistry and Biophysics, 346, 161–169.
   PubMed Web of Science ®Google Scholar
• YANAGIMOTO, T., Pron, S., SAWADA, M. and KAMATAKI, T., 1997, Mouse cytochrome P450 (Cyp3a11): predominant expression in liver and capacity to activate aflatoxin B1. Archives of Biochemistry and Biophysics, 340, 215–218.
   PubMed Web of Science ®Google Scholar
• ZHAO, X.-J. and Ismzmu, T., 1997, The in vitro hepatic metabolism of quinine in mice, rats and dogs: comparison with human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 283, 1168–1176.
   PubMed Web of Science ®Google Scholar